Cell Signaling
Head: Pavel Krejčí
Brno node
HOME INSTITUTION
Faculty of Medicine MU
RESEARCH PROGRAMME(S)
RP 1 - Molecular basis of cancer and molecular targets
RP 2 - Research and development of anticancer pharmaceuticals and therapeutic methods
There is more to receptor tyrosine kinases than meets the eye.
- Mission: Identify mechanisms of non-canonic interactions between transmembrane receptors; application of these interactions in oncogenesis.
- Vision: Understand mechanisms of receptor tyrosine kinase signal transduction.
More than 50 human pathologies are associated with mutations, amplifications, and translocations involving receptor tyrosine kinase (RTK) genes, including cancer, developmental defects, and metabolic, bone, and skin disorders. This makes RTKs attractive therapeutic targets; the development of drugs targeting RTK activity constitutes a major part of contemporary pharmacology. Many molecular mechanisms of RTK function are still unclear, which complicates progress in understanding the physiological functions of RTK in the organism, as well as progress in the application of RTK inhibitors in the treatment of pathologies caused by lesions in RTK genes.
COLLABORATION WITHIN THE NICR
Lukáš Trantírek
(Brno node, CEITEC MU)
SPECIALIZED EXPERTISE AND TECHNOLOGY
Analyses of receptor tyrosine kinase (RTK) signaling
Modern methods of targeting of the RTK signaling in vitro and in vivo
COLLABORATION WITH LARGE RESEARCH INFRASTRUCTURES AND RESEARCH CENTRES
Central European Institute of Technology at Masaryk University CEITEC MU